EUVIMEDEUVIMED entdecken
Systematische Übersicht

Definition of Response in Randomized Controlled Trials of Medications for Attention-Deficit/Hyperactivity Disorder Across the Lifespan: A Systematic Review

Sulagna Roy iD, Giuseppe Colacicco, Giorgia Frigeri, Fabio Tarantino, Emilia Matera, Maria Giuseppina Petruzzelli, Samuele Cortese

Journal of Child and Adolescent Psychopharmacology · 2025

DOI: 10.1089/cap.2025.0029 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2025. Verfasst von Sulagna Roy und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Psychology, University of Southampton, Southampton, United Kingdom. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Randomized Controlled Trials as Topic, Central Nervous System Stimulants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Randomized controlled trials (RCTs) are the gold standard for evaluating medication efficacy. The absence of a universal definition of treatment response, based on the degree of symptom improvement measured by standardized rating scales in the field of attention-deficit/hyperactivity disorder (ADHD), makes it difficult to compare treatment outcomes across RCTs. Here, we aimed to assess to what extent and how "treatment response" is defined across RCTs of ADHD medications.

Methods

We identified eligible RCTs via the MED-ADHD database (https://med-adhd.org/), which compiles RCTs evaluating the efficacy and safety of pharmacological treatments for children, adolescents, and adults with ADHD, based on a comprehensive search in multiple electronic databases, including PubMed, BIOSIS Previews, CINAHL, the Cochrane Central Registry of Controlled Trials, and EMBASE, up to 17 January 2025, alongside additional unpublished information gathered from manufacturers/study authors.

Results

Out of 167 RCTs in MED-ADHD, 88 defined treatment response based on reductions in ADHD core symptom severity using rating scale scores. The most frequently used threshold was a ≥30% reduction in attention-deficit/hyperactivity disorder (ADHD-RS) scores, with other RCTs using ≥25%, ≥40%, or ≥50%. In addition, RCTs applied similar cutoff values to alternative scales, including Conner's Adult ADHD Rating Scale, SNAP-IV, Adult ADHD Investigator Rating Scale, and Wender-Reimherr Adult Attention Deficit Disorder Scale. However, 79 studies did not specify any response threshold.

Conclusion

Our review underscores and quantitatively defines the inconsistency in the definition of treatment response across ADHD medication trials, highlighting the urgent need for the field to reach a consensus on the use of a standardized definition of "treatment response" for each rating scale, based on the percentage reduction in ADHD core symptom severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityRandomized Controlled Trials as TopicCentral Nervous System StimulantsHumansChildAdolescentAdultTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

attention-deficit/hyperactivity disorder (ADHD)pharmacological treatmentrandomized controlled trials (RCTs)standardized definitiontreatment response

Substanzen

Central Nervous System Stimulants

Autor:innen und Institutionen

  • School of Psychology, University of Southampton, Southampton, United Kingdom.
  • Centre for Innovation in Mental Health, University of Southampton, Southampton, United Kingdom.
  • DIBRAIN - Department of Biomedicine Translational and Neuroscience, University of Bari "Aldo Moro," Bari, Italy.
  • DiMePRe-J-Department of Precision and Regenerative Medicine-Jonic Area, University of Bari "Aldo Moro," Bari, Italy.
  • Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, United Kingdom.
  • Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

ORCID-Profile: Sulagna Roy

Zitieren

APA

Roy, S., Colacicco, G., Frigeri, G., Tarantino, F., Matera, E., Petruzzelli, M. G., & Cortese, S. (2025). Definition of Response in Randomized Controlled Trials of Medications for Attention-Deficit/Hyperactivity Disorder Across the Lifespan: A Systematic Review. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2025.0029

Vancouver

Roy S, Colacicco G, Frigeri G, Tarantino F, Matera E, Petruzzelli MG, et al. Definition of Response in Randomized Controlled Trials of Medications for Attention-Deficit/Hyperactivity Disorder Across the Lifespan: A Systematic Review. Journal of Child and Adolescent Psychopharmacology. 2025. doi:10.1089/cap.2025.0029

BibTeX
@article{Roy2025,
  author = {Roy, Sulagna and Colacicco, Giuseppe and Frigeri, Giorgia and Tarantino, Fabio and Matera, Emilia and Petruzzelli, Maria Giuseppina and Cortese, Samuele},
  title = {Definition of Response in Randomized Controlled Trials of Medications for Attention-Deficit/Hyperactivity Disorder Across the Lifespan: A Systematic Review},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2025},
  doi = {10.1089/cap.2025.0029}
}
Kostenlos starten →